Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3950-3956

  Gontijo, Aline Vidal Lacerda ^a,b,d   Grégoire, Nicolas ^a,b   Lamarche, Isabelle ^a,b   Gobin, Patrice ^a,c   Couet, William ^a,b,c   Marchand, Sandrine ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; AEROSOL; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; EPITHELIUM; INTRAPULMONARY DRUG ADMINISTRATION; LUNG LAVAGE; MALE; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; AEROSOL; ALGORITHM; ANIMAL; AREA UNDER THE CURVE; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PHARMACEUTICS; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRAVENOUS; AEROSOLS; ALGORITHMS; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOPHARMACEUTICS; BRONCHOALVEOLAR LAVAGE FLUID; COLISTIN; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84903192156     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02819-14     Document Type: Article

References (42)

1. Hagerman JK, Hancock KE, Klepser ME. 2006. Aerosolised antibiotics: a critical appraisal of their use. Exp. Opin. Drug Deliv. 3:71-86. http://dx.doi.org/10.1517/17425247.3.1.71.
2. Palmer LB. 2011. Aerosolized antibiotics in the intensive care unit. Clin. Chest Med. 32:559-574. http://dx.doi.org/10.1016/j.ccm.2011.05.012.
3. Michalopoulos A, Papadakis E. 2010. Inhaled anti-infective agents: emphasis on colistin. Infection 38:81-88. http://dx.doi.org/10.1007/s15010-009- 9148-6.
4. Michalopoulos AS. 2012. Aerosolized antibiotics: the past, present and future, with a special emphasis on inhaled colistin. Exp. Opin. Drug Deliv. 9:493-495. http://dx.doi.org/10.1517/17425247.2012.676039.
5. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958. http://dx.doi.org/10.1128/AAC.00035-06. (Pubitemid 43807511)
6. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341. http://dx.doi.org/10.1086/429323. (Pubitemid 40570245)
7. Nation RL, Li J. 2009. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22:535-543. http://dx.doi.org/10.1097/QCO.0b013e328332e672.
8. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601. http://dx.doi.org/10.1016/S1473-3099(06)70580-1.
9. Couet W, Gregoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin. Pharmacol. Ther. 89: 875- 879. http://dx.doi.org/10.1038/clpt.2011.48.
10. Couet W, Gregoire N, Marchand S, Mimoz O. 2012. Colistin pharmacokinetics: the fog is lifting. Clin. Microbiol. Infect. 18:30-39. http://dx.doi.org/10.1111/j.1469-0691.2011.03667.x.
11. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294. http://dx.doi.org/10.1128/AAC. 01733-10.
12. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob. Agents Chemother. 56: 4241-4249. http://dx.doi.org/10.1128/AAC.06426-11.
13. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob. Agents Chemother. 53:3430-3436. http://dx.doi.org/10.1128/AAC.01361-08.
14. Hewer SL. 2012. Inhaled antibiotics in cystic fibrosis: what's new? J. R. Soc. Med. 105(Suppl 2):S19 -S24. http://dx.doi.org/10.1258/jrsm.2012.12s004.
15. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ. 2012. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 38:1779-1786. http://dx.doi.org/10.1007/s00134-012-2628-7.
16. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. 2010. Inhaled colistin as adjunctive to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin. Microbiol. Infect. 16: 1230-1236. http://dx.doi.org/10.1111/j.1469-0691.2009.03040.x.
17. Athanassa ZE, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ. 2011. Monotherapy with inhaled colistin for the treatment of patients with ventilator-associated tracheobronchitis due to polymyxin-onlysusceptible Gram-negative bacteria. J. Hosp. Infect. 78:335-336. http://dx.doi.org/10.1016/ j.jhin.2011.04.004.
18. Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier JC, Mimoz O, Couet W. 2010. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob. Agents Chemother. 54:3702-3707. http://dx.doi.org/10.1128/AAC.00411-10.
19. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, Rouby JJ. 2010. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 36:1147-1155. http://dx.doi.org/10.1007/s00134-010-1879-4.
20. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57:306-311. http://dx.doi.org/10.1093/jac/dki461. (Pubitemid 43160174)
21. Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJH, Nation RL, McIntosh MP. 2014. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob. Agents Chemother. 58:2570-2579. http://dx.doi.org/10.1128/AAC.01705- 13.
22. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. 2004. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J. Cyst. Fibros. 3:23-28. http://dx.doi.org/10.1016/j.jcf.2003.12.005. (Pubitemid 38397020)
23. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. 2005. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit. Care 9:R53-R59. http://dx.doi.org/10.1186/cc3020.
24. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M. 2011. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa. BMC Infect. Dis. 11:317. http://dx.doi.org/10.1186/1471-2334-11-317.
25. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
26. Gontijo AVL, Brillault J, Grégoire N, Lamarche I, Gobin P, Couet W, Marchand S. 2014. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. Antimicrob. Agents Chemother. 58:3942-3949. http://dx.doi.org/10.1128/AAC. 02818-14.
27. Gobin P, Lemaitre F, Marchand S, Couet W, Olivier JC. 2010. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 54:1941-1948. http://dx.doi.org/10.1128/AAC.01367-09.
28. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532-538. (Pubitemid 16019939)
29. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J. 13:201-211. http://dx.doi.org/10.1208/s12248-011- 9257-x.
30. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 47:1766-1770. http://dx.doi.org/10.1128/AAC.47.5.1766-1770. 2003. (Pubitemid 36548571)
31. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504. http://dx.doi.org/10.1023/A:1012299115260. (Pubitemid 33151426)
32. Brillault J, De Castro WV, Harnois T, Kitzis A, Olivier JC, Couet W. 2009. P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob. Agents Chemother. 53:1457-1462. http://dx.doi.org/10.1128/AAC.01253-08.
33. Tronde A, Norden B, Jeppsson AB, Brunmark P, Nilsson E, Lennernas H, Bengtsson UH. 2003. Drug absorption from the isolated perfused rat lung: correlations with drug physicochemical properties and epithelial permeability. J. Drug Target. 11:61-74. http://dx.doi.org/10.1080/1061186031000086117. (Pubitemid 36527397)
34. Tronde A, Norden B, Marchner H, Wendel AK, Lennernas H, Bengtsson UH. 2003. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J. Pharm. Sci. 92:1216-1233. http://dx.doi.org/10.1002/jps.10386. (Pubitemid 36676468)
35. Bosquillon C. 2010. Drug transporters in the lung: do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99:2240-2255. http://dx.doi.org/10.1002/jps.21995.
36. Jin L, Li J, Nation RL, Nicolazzo JA. 2011. Impact of P-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. Antimicrob. Agents Chemother. 55:502-507. http://dx.doi.org/10.1128/AAC.01273-10.
37. Ma Z, Wang J, Nation RL, Li J, Turnidge JD, Coulthard K, Milne RW. 2009. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob. Agents Chemother. 53:2857-2864. http://dx.doi.org/10.1128/AAC.00030-09.
38. Koepsell H, Lips K, Volk C. 2007. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24:1227-1251. http://dx.doi.org/10.1007/s11095-007- 9254-z. (Pubitemid 46876495)
39. Ehrhardt C, Kneuer C, Bies C, Lehr CM, Kim KJ, Bakowsky U. 2005. Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm. Pharmacol. Ther. 18:165-170. http://dx.doi.org/10.1016/j.pupt.2004.11.007. (Pubitemid 40222110)
40. Mukherjee M, Pritchard DI, Bosquillon C. 2012. Evaluation of airinterfaced Calu-3 cell layers for investigation of inhaled drug interactions with organic cation transporters in vitro. Int. J. Pharm. 426:7-14. http://dx.doi.org/10.1016/j.ijpharm.2011.12.036.
41. Groneberg DA, Eynott PR, Doring F, Dinh QT, Oates T, Barnes PJ, Chung KF, Daniel H, Fischer A. 2002. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax 57:55-60. http://dx.doi.org/10.1136/thorax.57.1.55. (Pubitemid 34081545)
42. Groneberg DA, Fischer A, Chung KF, Daniel H. 2004. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport. Am. J. Respir. Cell Mol. Biol. 30:251-260. http://dx.doi.org/10.1165/rcmb.2003-0315TR. (Pubitemid 38315377)